ABEONA THERAPEUTICS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $3.61M.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $5.16M.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $140.00K.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $8.78M.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2021 was $831.00K, a 369.49% increase from fiscal 2020.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2020 was $177.00K, a 81.73% decline from fiscal 2019.
- ABEONA THERAPEUTICS INC. stock issued during period, value, stock options exercised for fiscal 2019 was $969.00K, a 56.82% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.78M 10-K · filed 2026-03-17 |
| 2025-09-30 | $5.16M 10-Q · filed 2025-11-12 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $831.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $140.00K 10-Q · filed 2022-11-14 | $833.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $24.00K 10-Q · filed 2022-08-11 | $693.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $667.00K 10-Q · filed 2022-05-13 | $844.00K derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $177.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $175.00K 10-Q · filed 2021-07-28 | |
| 2019-12-31 | $556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $969.00K 10-K · filed 2021-03-24 |
| 2019-06-30 | $385.00K 10-Q · filed 2020-08-10 | |
| 2019-03-31 | $28.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $2.24M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $79.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $481.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $1.69M 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $344.00K 10-K · filed 2020-03-16 | |
| 2017-09-30 | $8.00K 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $84.00K 10-Q · filed 2017-11-14 | |
| 2017-03-31 | $1.00K 10-Q · filed 2017-11-14 | |
| 2016-12-31 | $350.00K 10-K · filed 2019-03-18 | |
| 2013-12-31 | $29.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |